StockNews.com downgraded shares of Relx (NYSE:RELX – Free Report) from a buy rating to a hold rating in a report released on Tuesday morning.
Separately, Redburn Atlantic initiated coverage on shares of Relx in a report on Wednesday, January 8th. They set a “buy” rating on the stock.
View Our Latest Stock Report on Relx
Relx Price Performance
Relx Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.5586 per share. The ex-dividend date of this dividend is Friday, May 9th. This is an increase from Relx’s previous semi-annual dividend of $0.23. This represents a yield of 1.6%. Relx’s dividend payout ratio is 59.68%.
Institutional Investors Weigh In On Relx
Several hedge funds and other institutional investors have recently modified their holdings of RELX. CENTRAL TRUST Co increased its position in shares of Relx by 1,290.2% during the fourth quarter. CENTRAL TRUST Co now owns 570 shares of the technology company’s stock valued at $26,000 after buying an additional 529 shares during the period. Versant Capital Management Inc bought a new stake in shares of Relx during the fourth quarter valued at about $31,000. Transce3nd LLC bought a new stake in shares of Relx during the fourth quarter valued at about $40,000. Sierra Ocean LLC bought a new stake in shares of Relx during the fourth quarter valued at about $43,000. Finally, Brown Brothers Harriman & Co. increased its position in shares of Relx by 218.5% during the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company’s stock valued at $44,000 after buying an additional 662 shares during the period. 15.02% of the stock is currently owned by institutional investors.
Relx Company Profile
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Featured Articles
- Five stocks we like better than Relx
- Are Penny Stocks a Good Fit for Your Portfolio?
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- How to Profit From Growth Investing
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Short Selling – The Pros and Cons
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.